Skip to main
OCUL
OCUL logo

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix (OCUL) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocular Therapeutix Inc's estimated market value has increased to $4.44 billion, reflecting a positive sentiment driven by accelerated timelines for product approval and commercialization. The company's strategic changes in regulatory approach are expected to advance the approval process for its lead product, Axpaxli, by approximately 12-15 months, enhancing its competitive position in the market. Additionally, SOL-R's successful randomization of subjects highlights robust demand for its therapies, underscoring the company's strong growth potential as it seeks to address unmet needs in ophthalmic treatments.

Bears say

Ocular Therapeutix has reported significant losses since its inception, indicating challenges in achieving profitability. The company's market position is at risk due to competition from both existing therapies and emerging products targeting similar eye conditions, which could hinder market penetration and affect pricing strategies. Furthermore, potential delays in clinical development, regulatory approvals, or commercialization, coupled with any observed efficacy or safety concerns during Phase 3 studies, may lead to increased costs and limit the company's ability to successfully bring products to market.

Ocular Therapeutix (OCUL) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocular Therapeutix (OCUL) Forecast

Analysts have given Ocular Therapeutix (OCUL) a Buy based on their latest research and market trends.

According to 10 analysts, Ocular Therapeutix (OCUL) has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocular Therapeutix (OCUL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.